Background: Ultraviolet-A1 phototherapy has been used to treat many inflammatory dermatoses.

Aims: To determine the efficacy and safety of ultraviolet-A1 phototherapy in Asian skin.

Materials And Methods: We performed a review of records of patients undergoing ultraviolet-A1 phototherapy at our dermatology unit in Singapore from January 2007 to January 2011. Their electronic medical records were reviewed and a standardized questionnaire was filled up for data collection and tabulation. Chi-square or Fisher's exact tests were used to compare the difference in response between various groups for each characteristic. P value of < 0.05 was considered statistically significant.

Results: Our study comprised of 159 patients, of which 103 were patients with hand and foot eczema, 21 with atopic dermatitis, 17 with scleroderma and the remaining with miscellaneous dermatoses. Of these patients, 47.6% of patients with hand and feet eczema had good response after 10 sessions, which increased to 75% after 20 sessions and to 84.6% after 30 sessions. After 10 sessions, 47.6% of patients with atopic dermatitis had good response, which increased to 66.7% after 20 sessions. After 30 sessions, all the three remaining patients with atopic dermatitis experienced good response. For patients with scleroderma, only 11.8 and 10% had good response after 10 and 20 sessions, respectively, which increased to 40% after 30 sessions.

Limitations: Limitations of our study include its retrospective design and, consequently, the lack of standardized treatment protocol, as well as subjective assessment in terms of clinical improvement.

Conclusions: Ultraviolet-A1 phototherapy appears to be efficacious for the treatment of hand and foot eczema as well as atopic dermatitis. However, in patients with scleroderma, the response was partial and needed a longer duration of treatment.

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijdvl.IJDVL_751_17DOI Listing

Publication Analysis

Top Keywords

ultraviolet-a1 phototherapy
20
atopic dermatitis
16
good response
16
patients
9
phototherapy asian
8
patients hand
8
hand foot
8
foot eczema
8
476% patients
8
response sessions
8

Similar Publications

Phototherapy for the treatment of cutaneous graft-versus-host disease: A systematic review.

Photodermatol Photoimmunol Photomed

September 2024

Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.

Background: Cutaneous graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation. Phototherapy has been used to treat cutaneous GVHD, but data on its safety and efficacy are sparse.

Aim: Review the current medical literature regarding the efficacy, dosing, and safety of various types of phototherapies for the treatment of cutaneous GVHD.

View Article and Find Full Text PDF

Background/purpose: Mycosis fungoides (MF) is the most common variant of cutaneous T-cell lymphomas primarily involving the skin. Early-stage MF is characterised by non-specific skin lesions and non-diagnostic biopsies. While skin-focused treatments, such as PUVA and narrowband UVB (nbUVB), are the most frequently recommended treatments, the UVA1 efficacy has been researched in recent years.

View Article and Find Full Text PDF
Article Synopsis
  • Ultraviolet (UVA) A1 phototherapy has been an effective treatment for various skin conditions since the 1990s, yet its application remains limited to a few dermatology centers even after 30 years.
  • A study at a single center reviewed 740 patients treated from 1998 to 2022, assessing treatment outcomes and side effects, revealing significant improvements in several conditions, including morphea and skin sarcoidosis.
  • Despite showing good efficacy, the usage of UVA1 phototherapy has decreased over the years due to multiple factors, including possible changes in clinical practices and alternatives available.
View Article and Find Full Text PDF

Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use "at the age of biologics" remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They achieved a median final EASI score of 9.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!